Also, in the study conducted by Kawazoe et al.127 on 264 metastatic colorectal cancers (mCRC), the KRAS exon 2 mutation was calculated to be 34%, as the highest mutation rate. This evidence concerns the gene KRAS and metastatic colorectal cancer.